Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.61 |
| ▸ | CNR1 | P21554 | 11/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25245919 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL23484854 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL23484632 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL23484633 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL29611328 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL29611573 | 0.80 | CNR2 (0.74) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL10365457 | 0.77 | CNR2 (0.58) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL17414492 | 0.76 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL13990796 | 0.76 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 | |
| SCHEMBL4938816 | 0.76 | CNR2 (1.00) | CNR2CNR1NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695192-A2 | ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF | University of Connecticut (US) | 2026-02-18 | — | — | EP | claimed |
| US-12527839-B2 | Treatments for systemic sclerosis | ACCELERON PHARMA INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12198788-B2 | System for detecting an intraoral disease and determining a personalized treatment scheme and method of doing same | CANNIBITE BVBA (BE) | 2025-01-14 | — | — | US | claimed |
| WO-2024216279-A2 | ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-20070104741-A1 | Delivery of tetrahydrocannabinol | MURTY PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | claimed |
| US-20070037873-A1 | Airway remodeling treatments | MASSACHUSETTS, UNIVERSITY OF | 2007-02-15 | — | — | US | claimed |
| WO-2006117315-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| WO-2006117316-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| US-20060241165-A1 | Method and kit for regulation of microvascular tone | MOORE BOB M II | 2006-10-26 | — | — | US | claimed |
| US-20050070596-A1 | Methods for treatment of inflammatory diseases using CT-3 or analogs thereof | INDEVUS PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | claimed |
| WO-2004100893-A2 | METHODS FOR TREATMENT OF INFLAMMATORY DISEASES USING CT-3 OR ANALOGS THEREOF | INDEVUS PHARMACEUTICALS, INC. (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040186166-A1 | Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-09-23 | — | — | US | claimed |
| WO-2004058251-A1 | CANNABINOID ANALOGS AS PEROXISOME PROLIFERATOR ACTIVATED NUCLEAR RECEPTOR GAMMA ACTIVATORS | UNIVERSITY OF MASSACHUSETTS (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | CNR2 2315/4885CNR1 2110/4885NR1I2 1041/4885 |
| US-20050070596-A1 | Methods for treatment of inflammatory diseases using CT-3 or analogs thereof | PTGES3, PTGER3, CNR2 | CNR2 3/4885CNR1 4/4885NR1I2 1020/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CNR1 221/4885NR1I2 3198/4885 |
| US-20040186166-A1 | Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators | PPARA, PPARG, CNR1 | CNR2 4/4885CNR1 3/4885NR1I2 171/4885 |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | CNR2 2315/4885CNR1 2110/4885NR1I2 1041/4885 |
| US-12527839-B2 | Treatments for systemic sclerosis | TGFBR2, TGFBR1, SMAD2 | CNR2 2159/4885CNR1 2553/4885NR1I2 810/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | CNR2 2315/4885CNR1 2110/4885NR1I2 1041/4885 |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | CNR2 2315/4885CNR1 2110/4885NR1I2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.